The board of directors of Zhongzhi Pharmaceutical Holdings Limited announced that Ms. Jiang Li Xia has been re-designated from an executive Director to a non-executive Director of the company with effect from 19 September 2016. Mr. Cheng Jin Le has been appointed as executive Director of the company with effect from 19 September 2016. The board further announced that Ms. Chow Fung Ling has resigned as the company secretary of the company with effect from 19 September 2016. Following the resignation of Ms. Chow, Mr. Cheng Tat Hei has been appointed as the company secretary with effect from 19 September 2016. Following the resignation of Ms. Chow, Ms. Chow ceased to be the authorized representative of the company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Mr. Nicholas Cheng has been appointed as an authorized representative of the company with effect from 19 September 2016. Mr. Cheng is the vice general manager and chief engineer of the Group. He joined the Group in June 2003 and is responsible for overseeing the research and development of decoction pieces. Mr. Cheng has over 35 years of experience in the pharmaceutical industry. Prior to joining the Group, he served as the chief pharmacist of Chinese medicine in the Hubei Macheng People's Hospital. Mr. Nicholas Cheng has over 8 years of experience in the field of accounting, auditing and corporate finance. Mr. Nicholas Cheng joined the Group as the Head of Investment in April 2016. Prior to joining the Group, Mr. Nicholas Cheng worked for a type 6 licensed corporation under the SFO from July 2012 to April 2016 and Deloitte Touche Tohmatsu from January 2008 to July 2012.